MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-60.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
MNMD vs SILO vs CMPS vs ATAI vs CYBN
Revenue, margins, valuation, and 5-year total return — side by side.
SILO
Silo Pharma, Inc.
Biotechnology
Market Cap$2M
5Y Perf.+43.9%
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-85.6%
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.-80.9%
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-91.4%
MNMD vs SILO vs CMPS vs ATAI vs CYBN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNMD | SILO | CMPS | ATAI | CYBN |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Medical - Care Facilities | Medical - Pharmaceuticals | Biotechnology |
| Market Cap | $2.04B | $2M | $902M | $964M | $304M |
| Revenue (TTM) | $0.00 | $72K | $0.00 | $3M | $0.00 |
| Net Income (TTM) | $-238M | $-5M | $-288M | $-154M | $-123M |
| Gross Margin | — | -8.1% | — | -259.1% | — |
| Operating Margin | — | -74.5% | — | -34.6% | — |
| Total Debt | $0.00 | $0.00 | $21M | $25M | $0.00 |
| Cash & Equiv. | $258M | $4M | $150M | $18M | $135M |
MNMD vs SILO vs CMPS vs ATAI vs CYBN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNMD
SILO
CMPS
ATAI
CYBN
| Stock | Jun 21 | Apr 26 | Return |
|---|---|---|---|
| Mind Medicine (Mind… (MNMD) | 100 | 40.0 | -60.0% |
| Silo Pharma, Inc. (SILO) | 100 | 143.9 | +43.9% |
| COMPASS Pathways plc (CMPS) | 100 | 14.4 | -85.6% |
| Atai Beckley N.V (ATAI) | 100 | 19.1 | -80.9% |
| Cybin Inc. (CYBN) | 100 | 8.6 | -91.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNMD vs SILO vs CMPS vs ATAI vs CYBN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CYBN leads in 2 of 6 categories (5-stock set), making it the strongest pick for profitability and margin quality and operational efficiency and capital deployment. Mind Medicine (MindMed) Inc. is the stronger pick specifically for recent price momentum and sentiment. SILO and CMPS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 5.1% 10Y total return vs SILO's 20.0%
- +214.0% vs SILO's -48.1%
Best for: long-term compounding
SILO
Silo Pharma, Inc.
The Growth Play
SILO ranks third and is worth considering specifically for growth exposure.
- Rev growth 0.0%, EPS growth 0.8%, 3Y rev CAGR 0.4%
- 0.0% revenue growth vs MNMD's -96.9%
Best for: growth exposure
CMPS
COMPASS Pathways plc
The Income Pick
CMPS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.33
- Lower volatility, beta 1.33, current ratio 0.77x
- Beta 1.33 vs SILO's 2.21
Best for: income & stability and sleep-well-at-night
ATAI
Atai Beckley N.V
The Healthcare Pick
Among these 5 stocks, ATAI doesn't own a clear edge in any measured category.
Best for: healthcare exposure
CYBN
Cybin Inc.
The Defensive Pick
CYBN carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 1.52, current ratio 7.75x
- 3.2% margin vs SILO's -70.4%
- -58.3% ROA vs CMPS's -106.8%
Best for: defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SILO | 0.0% revenue growth vs MNMD's -96.9% |
| Quality / Margins | CYBN | 3.2% margin vs SILO's -70.4% |
| Stability / Safety | CMPS | Beta 1.33 vs SILO's 2.21 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs SILO's -48.1% |
| Efficiency (ROA) | CYBN | -58.3% ROA vs CMPS's -106.8% |
MNMD vs SILO vs CMPS vs ATAI vs CYBN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2024
Segment breakdown not available.
MNMD vs SILO vs CMPS vs ATAI vs CYBN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNMDLAGGINGCYBN
Who Leads Where
ATAI leads in 1 of 6 categories
SILO leads 1 • MNMD leads 1 • CMPS leads 0 • CYBN leads 0 • 2 tied
Explore the data ↓CYBNCybin Inc.
0leads
CMPSCOMPASS Pathways plc
0leads
ATAIAtai Beckley N.V
1leads
SILOSilo Pharma, Inc.
1leads
MNMDMind Medicine (MindMe…
1leads
6 Total Categories
CATEGORYLEADERvs SILOvs ATAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATAI5/6
Valuation MetricsMultiples, price ratios, and targets
SILO2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
MNMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATAI leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATAI and CYBN operate at a comparable scale, with $3M and $0 in trailing revenue. ATAI is the more profitable business, keeping -51.1% of every revenue dollar as net income compared to SILO's -70.4%. On growth, ATAI holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $72,102 | $0 | $3M | $0 |
| EBITDAEarnings before interest/tax | -$191M | -$5M | -$179M | -$103M | -$147M |
| Net IncomeAfter-tax profit | -$238M | -$5M | -$288M | -$154M | -$123M |
| Free Cash FlowCash after capex | -$174M | -$5M | -$157M | -$90M | -$106M |
| Gross MarginGross profit ÷ Revenue | — | -8.1% | — | -2.6% | — |
| Operating MarginEBIT ÷ Revenue | — | -74.5% | — | -34.6% | — |
| Net MarginNet income ÷ Revenue | — | -70.4% | — | -51.1% | — |
| FCF MarginFCF ÷ Revenue | — | -66.6% | — | -29.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | 0.0% | — | +17.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -163.0% | +45.5% | -58.7% | -75.0% | -8.2% |
ATAI leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
SILO leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $2.0B | $2M | $902M | $964M | $304M |
| Enterprise ValueMkt cap + debt − cash | $1.8B | -$2M | $774M | $971M | $205M |
| Trailing P/EPrice ÷ TTM EPS | -10.04x | -0.35x | -3.05x | -4.31x | -13.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 26.12x | — | 3130.37x | — |
| Price / BookPrice ÷ Book value/share | 5.56x | 0.31x | — | 5.51x | 6.52x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
SILO leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — MNMD and CYBN each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
CYBN delivers a -81.0% return on equity — every $100 of shareholder capital generates $-81 in annual profit, vs $-3 for CMPS. On the Piotroski fundamental quality scale (0–9), MNMD scores 3/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -102.5% | -101.4% | -3.4% | -96.4% | -81.0% |
| ROA (TTM)Return on assets | -70.7% | -79.5% | -106.8% | -64.3% | -58.3% |
| ROICReturn on invested capital | -3.9% | -186.7% | — | -45.0% | -115.8% |
| ROCEReturn on capital employed | -52.2% | -74.0% | -2.5% | -50.4% | -54.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 2 | 2 | 3 |
| Debt / EquityFinancial leverage | — | — | — | 0.21x | — |
| Net DebtTotal debt minus cash | -$258M | -$4M | -$129M | $7M | -$135M |
| Cash & Equiv.Liquid assets | $258M | $4M | $150M | $18M | $135M |
| Total DebtShort + long-term debt | $0 | $0 | $21M | $25M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -21.81x | -1053.72x | -52.40x | -68.93x | — |
Evenly matched — MNMD and CYBN each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SILO five years ago would be worth $16,471 today (with dividends reinvested), compared to $968 for CYBN. Over the past 12 months, MNMD leads with a +214.0% total return vs SILO's -48.1%. The 3-year compound annual growth rate (CAGR) favors MNMD at 82.7% vs SILO's -42.6% — a key indicator of consistent wealth creation.
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +51.7% | +25.0% | +43.4% | +3.6% | -26.4% |
| 1-Year ReturnPast 12 months | +214.0% | -48.1% | +151.1% | +188.5% | -1.9% |
| 3-Year ReturnCumulative with dividends | +510.3% | -81.1% | +11.0% | +99.5% | -49.8% |
| 5-Year ReturnCumulative with dividends | -57.9% | +64.7% | -72.4% | -79.8% | -90.3% |
| 10-Year ReturnCumulative with dividends | +512.1% | +20.0% | -67.6% | -47.7% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +82.7% | -42.6% | +3.5% | +25.9% | -20.5% |
MNMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MNMD and CMPS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CMPS is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than SILO's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs SILO's 37.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 2.21x | 1.33x | 1.48x | 1.52x |
| 52-Week HighHighest price in past year | $21.09 | $1.13 | $10.21 | $6.75 | $9.83 |
| 52-Week LowLowest price in past year | $6.03 | $0.22 | $2.25 | $1.29 | $5.50 |
| % of 52W HighCurrent price vs 52-week peak | +98.1% | +37.2% | +92.0% | +59.4% | +62.0% |
| RSI (14)Momentum oscillator 0–100 | 64.9 | 47.0 | 68.1 | 51.5 | 35.5 |
| Avg Volume (50D)Average daily shares traded | 792K | 4.6M | 3.7M | 6.0M | 292K |
Evenly matched — MNMD and CMPS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MNMD as "Buy", CMPS as "Buy", ATAI as "Buy", CYBN as "Buy". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | MNMDMind Medicine (Mi… | SILOSilo Pharma, Inc. | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $20.00 | — | $17.83 | $12.00 | — |
| # AnalystsCovering analysts | 1 | — | 13 | 4 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +9.2% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATAI leads in 1 of 6 categories (Income & Cash Flow). SILO leads in 1 (Valuation Metrics). 2 tied.
Best OverallMind Medicine (MindMed) Inc. (MNMD)Leads 1 of 6 categories
Loading custom metrics...
MNMD vs SILO vs CMPS vs ATAI vs CYBN: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is MNMD or SILO or CMPS or ATAI or CYBN a better buy right now?
Analysts rate Mind Medicine (MindMed) Inc.
(MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MNMD or SILO or CMPS or ATAI or CYBN?
Over the past 5 years, Silo Pharma, Inc.
(SILO) delivered a total return of +64. 7%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MNMD or SILO or CMPS or ATAI or CYBN?
By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.
33β versus Silo Pharma, Inc. 's 2. 21β — meaning SILO is approximately 66% more volatile than CMPS relative to the S&P 500.
04Which is growing faster — MNMD or SILO or CMPS or ATAI or CYBN?
On earnings-per-share growth, the picture is similar: Cybin Inc.
grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Over a 3-year CAGR, SILO leads at 0. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MNMD or SILO or CMPS or ATAI or CYBN?
Mind Medicine (MindMed) Inc.
(MNMD) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MNMD or SILO or CMPS or ATAI or CYBN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MNMD or SILO or CMPS or ATAI or CYBN better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Silo Pharma, Inc. (SILO) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, SILO: +20. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MNMD and SILO and CMPS and ATAI and CYBN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.